October 3rd 2022
This week's edition of the Mainstream Patient features stories about recommended acne solutions from dermatologists, Latinx-owned beauty brands, the latest skin care trend of "skin energy," and more.
September 15th 2022
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Advances in™ Hidradenitis Suppurativa (HS): Optimizing the Management Approach with Available and Emerging Treatments
View More
An Animated View of Alopecia Areata to Advance Our Approaches to Patient Management
View More
Individualizing Treatment in Moderate-to-Severe Atopic Dermatitis through Improved Clinician-Patient Communication
View More
Burst CME: Improving Outcomes for Your Patient with Vitiligo
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Facing the Changing Landscape for Neuromodulators and Dermal Fillers
View More
Community Practice Connections™: Multidisciplinary Management of BPDCN: Strategies for Differential Diagnosis and Integrating Novel Targeted Therapy
View More
Clinical ShowCase™ in Atopic Dermatitis: Personalized Management Plans for Pediatric Patients
View More
Cases and Conversations™: Enhancing Diagnosis and Evaluation of Generalized Pustular Psoriasis in Advanced Practice Settings
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Addressing Challenges in the Management of HS in Special Populations
View More
Best Practice in the Multidisciplinary Care of the Patient with HS
View More
Hirsutism may signal underlying disorder
October 1st 2006National report - Hirsutism may signal an underlying medical condition including polycystic ovary syndrome (PCOS) or Cushing's syndrome that dermatologists can help detect without laboratory tests, says Marcelle Cedars, M.D., who also suggests several treatment plans available to the dermatologist.
HPV Vaccination: Clinical Issues
October 1st 2006Gardasil (Merck) is made of virus-like particles - copies of the capsids or the outer shell of the virus; there is no DNA - therefore, it is impossible to become infected with HPV through vaccination. The vaccine stimulates an antibody response to that outer coating of the virus, and is 100 percent protective if administered prior to exposure to the four strains of HPV that it protects against.
Clinicians finding multiple uses for new line of topical hyaluronic acid products
September 1st 2006National report - Experience with a new topical product line containing hyaluronic acid sodium salt 0.2 percent (Bionect, JSJ Pharmaceuticals) indicates it may be useful for optimizing the healing environment when the skin barrier has been disrupted by various dermatologic treatments.
Vaccine against HPV on its way
August 1st 2006Philadelphia - Human papillomaviruses (HPV) are responsible for a variety of proliferative diseases in the squamous epithelia of humans, causing localized benign proliferations (e.g. the common warts), some of which have the potential to progress to cancer.
Vascular lesions: Avoiding diagnostic pitfalls
August 1st 2006Seattle - Accurate diagnosis of vascular proliferations can be both difficult and critical, given a relatively wide disparity in clinical outcome between the different types of lesions, according to Omar P. Sangueza, M.D., professor and director of dermatopathology at the Wake Forest University School of Medicine, Winston-Salem, N.C.
Nonsurgical techniques for treating skin cancer
August 1st 2006Noninvasive skin cancer treatment can be an attractive option for patients, especially in this age of new techniques and pharmaceutical discovery. But with new and exciting advancements often come new and complex questions. Dermatology Times asked Ronald Moy, M.D., a Los Angeles Mohs surgeon and former professor at the University of California, Los Angeles, and Marc D. Brown, M.D., a Mohs surgeon and professor of dermatology and otolaryngology at the University of Rochester Medical School, Rochester, N.Y., to discuss noninvasive skin cancer treatments.
Ron Reagan pleads for support for stem cell research
July 29th 2006Stem cell research is among the "one or two paradigm-changing medical breakthroughs" that may occur in a lifetime, and it's vitally needed to bring hope to millions, says Ron Reagan, son of the late President Ronald Reagan. Mr. Reagan addressed the Friday morning plenary session at the American Academy of Dermatology's Academy '06, couching in impassioned and often stinging political commentary his plea for support for stem cell research.
Approval of HPV vaccine heralded for implications in preventing cervical cancer
July 28th 2006The very recent approval of the quadrivalent human papilloma virus (HPV) virus-like particle vaccine (Gardasil) is the biggest breakthrough in medicine in the 21st century so far because its prevents infection with the virus that is the second leading cause of cancer deaths in women worldwide, says Stephen K. Tyring, M.D., Ph.D.
Panniculitis - Reviewing the basics
July 28th 2006The most common cause of primary septal panniculitis is erythema nodosum. The clinical and microscopic features causing this disease are well known to the experienced dermatologist. The most common etiologic agents in erythema nodosum include infections (e.g. group A beta hemolytic strep, deep fungal and viral), drugs (e.g. oral contraceptives and sulfonamides), inflammatory bowel disease, sarcoidosis, pregnancy and malignancy.Dr. Robinson-Bostom says that, "We have found new associations concerning the etiologies in erythema nodosum. These include hepatitis C and HIV infections, all trans retinoic acid, echinacea herbal therapy, celiac disease, as well as carcinoid syndrome."
Immune response modifier post-op
July 1st 2006San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Immune response modifier post-op
July 1st 2006San Francisco - Results from several studies performed with imiquimod 5 percent cream (Aldara, 3M Pharmaceuticals) suggest that the immune response modifier may have a role as a surgical adjuvant for improving local tumor control and/or to enhance scar appearance, says James M. Spencer, M.D., M.S., clinical professor of dermatology, Mt. Sinai School of Medicine, New York.
Clearing confusion about destruction codes
June 1st 2006CPT codes 17000, 17003 and 17004 are the bread-and-butter codes ofmost dermatologists. Actinic keratoses, warts and other benignlesions such as seborrheic keratoses, condylomata and papillomataare the most common types of lesions treated by the destructionmethod. Per CPT, the definition of destruction means "the ablationof benign, premalignant or malignant tissues by any method, with orwithout curettement, including local anesthesia, and not usuallyrequiring closure.
First link established between human papillomavirus and SCC
June 1st 2006National report - Researchers at Dartmouth Medical Schoolhave for the first time established an association betweeninfection with certain strains of human papillomavirus (HPV) andincreased risk for developing squamous cell carcinoma (SCC).